Zymeworks, Inc. (ZYME)
25.15
-0.69
(-2.67%)
USD |
NASDAQ |
Nov 18, 12:41
Zymeworks Total Liabilities (Quarterly) : 918.16M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 918.16M |
| June 30, 2026 | 316.60M |
| March 31, 2026 | 314.63M |
| December 31, 2025 | 78.03M |
| September 30, 2025 | 77.20M |
| June 30, 2025 | 73.88M |
| March 31, 2025 | 100.56M |
| December 31, 2024 | 124.32M |
| September 30, 2024 | 120.17M |
| June 30, 2024 | 109.47M |
| March 31, 2024 | 115.75M |
| December 31, 2023 | 116.07M |
| September 30, 2023 | 132.02M |
| June 30, 2023 | 153.14M |
| March 31, 2023 | 127.20M |
| December 31, 2022 | 155.77M |
| September 30, 2022 | 120.50M |
| June 30, 2022 | 146.69M |
| March 31, 2022 | 147.53M |
| December 31, 2021 | 140.04M |
| Date | Value |
|---|---|
| September 30, 2021 | 141.43M |
| June 30, 2021 | 150.48M |
| March 31, 2021 | 112.91M |
| December 31, 2020 | 128.45M |
| September 30, 2020 | 139.36M |
| June 30, 2020 | 115.60M |
| March 31, 2020 | 114.16M |
| December 31, 2019 | 122.52M |
| September 30, 2019 | 90.51M |
| June 30, 2019 | 80.53M |
| March 31, 2019 | 68.27M |
| December 31, 2018 | 63.87M |
| September 30, 2018 | 24.77M |
| June 30, 2018 | 24.53M |
| March 31, 2018 | 19.01M |
| December 31, 2017 | 15.53M |
| September 30, 2017 | 17.15M |
| June 30, 2017 | 17.62M |
| March 31, 2017 | 30.18M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| AbbVie, Inc. | 152.22B |
| Faeth Therapeutics, Inc. | 11.08M |
| ACADIA Pharmaceuticals, Inc. | 406.66M |
| Alnylam Pharmaceuticals, Inc. | 4.391B |
| Anika Therapeutics, Inc. | 52.02M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.176B |
| Shareholders Equity (Quarterly) | 258.25M |
| Debt to Equity Ratio | 2.518 |
| Current Ratio | 3.297 |
| Net Debt Paydown Yield | -6.65% |